Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Pirtobrutinib

FDA-approved product (tablet, oral), marketed as Jaypirca.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Pirtobrutinib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Mantle cell lymphoma
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Bruton's tyrosine kinase (btk) inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA49.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli38.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae29.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis64.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Pirtobrutinib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.7 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Pirtobrutinib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

    NCT04623541 · start 2020-11-25

    Registered record
    Registry ID
    NCT04623541
    Conditions
    Relapsed/Refractory Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Richter's Syndrome; Treatment-naïve High Risk Chronic Lymphocytic Leukemia
    Interventions
    Epcoritamab; Epcoritamab; rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Venetoclax; Epcoritamab; Lenalidomide; Epcoritamab; Pirtobrutinib; Epcoritamab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Active not recruiting
    Start
    2020-11-25
    Completion
    2028-02
    Enrolment
    194

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRelapsed/Refractory Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Richter's Syndrome; Treatment-naïve High Risk Chronic Lymphocytic Leukemia
    InterventionEpcoritamab; Epcoritamab; rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Venetoclax +5 more
    PhasePhase 1 / Phase 2
    Registry statusActive not recruiting

  • A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Different Formulations of Midazolam in Healthy Participants

    NCT06180967 · start 2020-09-03

    Registered record
    Registry ID
    NCT06180967
    Conditions
    Healthy
    Interventions
    Midazolam Syrup; Midazolam Solution; Pirtobrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-09-03
    Completion
    2020-10-20
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionMidazolam Syrup; Midazolam Solution; Pirtobrutinib
    PhasePhase 1
    Registry statusCompleted

  • Study of the Effect of Food and a Proton Pump Inhibitor (PPI; Omeprazole) on LOXO-305 in Healthy Participants

    NCT05134350 · start 2020-02-06

    Registered record
    Registry ID
    NCT05134350
    Conditions
    Healthy Volunteers
    Interventions
    LOXO-305; Omeprazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-02-06
    Completion
    2020-03-23
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionLOXO-305; Omeprazole
    PhasePhase 1
    Registry statusCompleted

  • A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

    NCT03740529 · start 2019-03-15

    Registered record
    Registry ID
    NCT03740529
    Conditions
    Chronic Lymphocytic Leukemia; Waldenstrom Macroglobulinemia; Mantle Cell Lymphoma; Marginal Zone Lymphoma; B-cell Lymphoma; Small Lymphocytic Lymphoma
    Interventions
    Pirtobrutinib; Venetoclax; Rituximab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2019-03-15
    Completion
    2025-12-23
    Enrolment
    803

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Lymphocytic Leukemia; Waldenstrom Macroglobulinemia; Mantle Cell Lymphoma; Marginal Zone Lymphoma +2 more
    InterventionPirtobrutinib; Venetoclax; Rituximab
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

    NCT03666000 · start 2019-03-11

    Registered record
    Registry ID
    NCT03666000
    Conditions
    Non-Hodgkin Lymphoma; B-cell Acute Lymphoblastic Leukemia; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
    Interventions
    Azer-cel; Fludarabine; Cyclophosphamide; IL-2; Ibrutinib, Acalabrutinib, Zanubrutinib, or Pirtobrutinib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2019-03-11
    Completion
    2027-06
    Enrolment
    135

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Hodgkin Lymphoma; B-cell Acute Lymphoblastic Leukemia; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
    InterventionAzer-cel; Fludarabine; Cyclophosphamide; IL-2 +1 more
    PhasePhase 1
    Registry statusRecruiting